Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1976 1
1983 1
1984 1
1987 1
1988 1
1990 2
1991 1
1993 1
1994 2
1998 1
1999 3
2001 2
2003 1
2004 1
2005 2
2006 1
2007 3
2008 3
2009 7
2010 3
2011 3
2012 2
2013 1
2016 2
2017 2
2018 3
2019 4
2020 4
2021 4
2022 7
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Epidermolysis bullosa simplex 1A, generalized severe"
Page 1
Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa.
Guide SV, Gonzalez ME, Bağcı IS, Agostini B, Chen H, Feeney G, Steimer M, Kapadia B, Sridhar K, Quesada Sanchez L, Gonzalez F, Van Ligten M, Parry TJ, Chitra S, Kammerman LA, Krishnan S, Marinkovich MP. Guide SV, et al. N Engl J Med. 2022 Dec 15;387(24):2211-2219. doi: 10.1056/NEJMoa2206663. N Engl J Med. 2022. PMID: 36516090 Clinical Trial.
BACKGROUND: Dystrophic epidermolysis bullosa is a rare genetic blistering skin disease caused by mutations in COL7A1, which encodes type VII collagen (C7). ...METHODS: We conducted a phase 3, double-blind, intrapatient randomized, placebo-controlled trial …
BACKGROUND: Dystrophic epidermolysis bullosa is a rare genetic blistering skin disease caused by mutations in COL7A1, which en …
Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review.
Martina E, Diotallevi F, Radi G, Campanati A, Offidani A. Martina E, et al. Toxins (Basel). 2021 Feb 5;13(2):120. doi: 10.3390/toxins13020120. Toxins (Basel). 2021. PMID: 33562846 Free PMC article.
The best-reported evidence concerns focal idiopathic hyperhidrosis, Raynaud phenomenon, suppurative hidradenitis, Hailey-Hailey disease, epidermolysis bullosa simplex Weber-Cockayne type, Darier's disease, pachyonychia congenita, aquagenic keratoderma, alopec …
The best-reported evidence concerns focal idiopathic hyperhidrosis, Raynaud phenomenon, suppurative hidradenitis, Hailey-Hailey disease, …
In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial.
Gurevich I, Agarwal P, Zhang P, Dolorito JA, Oliver S, Liu H, Reitze N, Sarma N, Bagci IS, Sridhar K, Kakarla V, Yenamandra VK, O'Malley M, Prisco M, Tufa SF, Keene DR, South AP, Krishnan SM, Marinkovich MP. Gurevich I, et al. Nat Med. 2022 Apr;28(4):780-788. doi: 10.1038/s41591-022-01737-y. Epub 2022 Mar 28. Nat Med. 2022. PMID: 35347281 Free PMC article. Clinical Trial.
Recessive dystrophic epidermolysis bullosa (RDEB) is a lifelong genodermatosis associated with blistering, wounding, and scarring caused by mutations in COL7A1, the gene encoding the anchoring fibril component, collagen VII (C7). ...Subsequently, a randomized …
Recessive dystrophic epidermolysis bullosa (RDEB) is a lifelong genodermatosis associated with blistering, wounding, and scarr …
Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study.
Kern JS, Sprecher E, Fernandez MF, Schauer F, Bodemer C, Cunningham T, Löwe S, Davis C, Sumeray M, Bruckner AL, Murrell DF; EASE investigators. Kern JS, et al. Br J Dermatol. 2023 Jan 23;188(1):12-21. doi: 10.1093/bjd/ljac001. Br J Dermatol. 2023. PMID: 36689495 Clinical Trial.
BACKGROUND: Epidermolysis bullosa (EB) is a heterogeneous group of rare, difficult-to-treat, inherited multisystem diseases affecting epithelial integrity. ...AEs were predominantly of mild-to-moderate intensity (4.6% were severe). CONCLUSIONS: Oleogel-S10 is …
BACKGROUND: Epidermolysis bullosa (EB) is a heterogeneous group of rare, difficult-to-treat, inherited multisystem diseases af …
Topical Diacerein Ointment for Epidermolysis Bullosa Simplex: A Review.
Limmer AL, Nwannunu CE, Shah R, Coleman K, Patel RR, Mui UN, Tyring SK. Limmer AL, et al. Skin Therapy Lett. 2019 May;24(3):7-9. Skin Therapy Lett. 2019. PMID: 31095348 Free article. Review.
Epidermolysis bullosa (EB) is a group of rare mucocutaneous fragility disorders often presenting in infancy and early childhood with painful blistering of the skin and mucous membranes. The severity of EB blister burden varies by disease subtype. Studies have shown …
Epidermolysis bullosa (EB) is a group of rare mucocutaneous fragility disorders often presenting in infancy and early childhoo …
Epidermolysis bullosa simplex generalized severe induces a T helper 17 response and is improved by apremilast treatment.
Castela E, Tulic MK, Rozières A, Bourrat E, Nicolas JF, Kanitakis J, Vabres P, Bessis D, Mazereeuw J, Morice-Picard F, Baty D, Berard F, Lacour JP, Passeron T, Chiaverini C. Castela E, et al. Br J Dermatol. 2019 Feb;180(2):357-364. doi: 10.1111/bjd.16897. Epub 2018 Dec 2. Br J Dermatol. 2019. PMID: 29932457 Clinical Trial.
BACKGROUND: Epidermolysis bullosa simplex generalized severe (EBS-gen sev) is a genetic disorder caused by mutation in the KRT5 or KRT14 genes. ...A second multicentre prospective study was conducted on 10 patients with severe EBS-gen sev …
BACKGROUND: Epidermolysis bullosa simplex generalized severe (EBS-gen sev) is a genetic disorder caused b …
Diacerein 1% Ointment for the Treatment of Epidermolysis Bullosa Simplex: A Randomized, Controlled Trial.
Teng J, Paller AS, Bruckner AL, Murrell DF, Mellerio JE, Bodemer C, Martinez AE, Lugo-Somolinos A, Sprecher E, Laimer M, Wally V, Chan YM, Lin SY, Spellman M, Bauer JW. Teng J, et al. J Drugs Dermatol. 2023 Jun 1;22(6):599-604. doi: 10.36849/JDD.7108. J Drugs Dermatol. 2023. PMID: 37276163 Clinical Trial.
BACKGROUND: In epidermolysis bullosa simplex (EBS), epithelial structural fragility results in blisters and erosions. ...CONCLUSIONS: Although there was no significant difference in outcomes between the groups, further study may elucidate the effects of diace …
BACKGROUND: In epidermolysis bullosa simplex (EBS), epithelial structural fragility results in blisters and erosions. . …
Keratin disorders: from gene to therapy.
McLean WH, Moore CB. McLean WH, et al. Hum Mol Genet. 2011 Oct 15;20(R2):R189-97. doi: 10.1093/hmg/ddr379. Epub 2011 Sep 2. Hum Mol Genet. 2011. PMID: 21890491 Review.
Recent advances in RNA interference therapeutics, particularly in the form of small-interfering RNAs, represent a potential therapy route for keratin disorders through selectively silencing the mutant allele. To date, mutant-specific siRNAs for epidermolysis bullosa …
Recent advances in RNA interference therapeutics, particularly in the form of small-interfering RNAs, represent a potential therapy route fo …
Application of topical gentamicin-a new era in the treatment of genodermatosis.
Wang S, Yang Z, Liu Y, Zhao MT, Zhao J, Zhang H, Liu ZY, Wang XL, Ma L, Yang YH. Wang S, et al. World J Pediatr. 2021 Dec;17(6):568-575. doi: 10.1007/s12519-021-00469-2. Epub 2021 Nov 17. World J Pediatr. 2021. PMID: 34787828 Review.
BACKGROUND: The clinical use of gentamicin always lies in its antimicrobial activity in the past as an aminoglycoside antibiotic. ...RESULTS: The application of gentamicin in genodermatosis yielded promising results, both in vivo and in vitro, including Nagashima-type palm …
BACKGROUND: The clinical use of gentamicin always lies in its antimicrobial activity in the past as an aminoglycoside antibiotic. ... …
Skin cleansing and topical product use in patients with epidermolysis bullosa: Results from a multicenter database.
Shayegan LH, Levin LE, Galligan ER, Lucky AW, Bruckner AL, Pope E, Lara-Corrales I, Wiss K, McCuaig CC, Garzon MC, Eichenfield LF, Hook KP, Browning JC, Schachner LA, Perman MJ, Castelo-Soccio L, Levy ML, Glick SA, Morel KD. Shayegan LH, et al. Pediatr Dermatol. 2020 Mar;37(2):326-332. doi: 10.1111/pde.14102. Epub 2020 Jan 15. Pediatr Dermatol. 2020. PMID: 31944391
BACKGROUND/OBJECTIVES: Epidermolysis bullosa (EB) comprises a group of inherited skin blistering diseases. ...METHODS: This cross-sectional, observational study included data collected from patients with EB enrolled in the Epidermolysis Bullosa Charact …
BACKGROUND/OBJECTIVES: Epidermolysis bullosa (EB) comprises a group of inherited skin blistering diseases. ...METHODS: This cr …
68 results